Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.
Cambia Health Solutions, a Portland, OR-based nonprofit, has led a $17.5 million financing for medical image network LifeImage--which claims to be the largest, most utilized network for exchanging medical images.
Medtronic, known mostly for its high-priced medical devices, is looking for some deals in China as it chases low-price customers for its line of "value products."
Since Lupin issued disappointing earnings reports to the India stock market the past three quarters, it feels the need to go out and buy the sales it needs to please investors. It plans to do so by acquiring enough other companies to add $1 billion to its sales revenues and make Lupin a $5 billion drug maker within three years.
Vital Access has secured a $10 million credit facility from Deerfield Management to expand marketing of its FDA-cleared implant to make it easier to access the vascular system of end-stage renal disease patients for hemodialysis. The cash is also intended to invest in additional vascular access products that might stem from the company's platform.
In an agreement expected to hurt drugmakers more than any other entity, the government of Australia has settled a budget dispute with the nation's pharmacies. The settlement, to begin July 1, includes payments to drugstores of U.S.$2.2 billion over 5 years.
Micro-cap NeuroMetrix has managed to raise $14.7 million via a complex, warrant-laden deal, despite the fact that its market cap continues to hover right around $10 million. The company is betting that it has a winner in its Quell over-the-counter pain relief device that FDA cleared in July 2014.
Vertex CEO Jeff Leiden took home a pretty penny last year, nabbing a $45.8 million pay package and ranking No. 40 among the highest-paid U.S. execs at publicly traded companies. But not everyone is happy with Leiden's hefty paycheck--and shareholders should do something about it, corporate governance adviser Institutional Shareholder Services told Bloomberg.
SI-Bone gained FDA clearance for its iFuse Implant System in November 2008 and a CE mark in November 2010. Now, it's brought in a new CFO and a $21 million cash infusion to help ramp up sales and, perhaps, to ready it for an IPO. The news comes after the startup revealed positive 6-month data and its surgical category gained a reimbursement code earlier this year.
Med techs are looking to revive public market interest. Several IPOs priced during the first few months of the year--but there's been a lull lately. Custom joint replacement maker ConforMIS is readying an IPO to raise up to $172.5 million, while gastrointestinal endoscopy player EndoChoice has set terms to raise $100 million. Also, Palo Alto, CA-based, breast tissue expansion company AirXpander is starting an IPO to raise A$36.5 million (US $28.3 million) on the Australian Securities Exchange.